Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

BACKGROUND: Radium-223 dichloride (radium-223), a first-in-class α-emitting radiopharmaceutical, is recommended in both pre- and post-docetaxel settings in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases based on overall survival benefit demonstrated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843190/
https://www.ncbi.nlm.nih.gov/pubmed/26912557
http://dx.doi.org/10.1093/annonc/mdw065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843190/
https://www.ncbi.nlm.nih.gov/pubmed/26912557
http://dx.doi.org/10.1093/annonc/mdw065

Ejemplares similares